Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

4.8K
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
4.8K
Metastasis02:30

Metastasis

6.8K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026
Same author

No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

NPJ precision oncology·2026
Same author

Highlights from the 27th European Congress on Gynecological Oncology in Copenhagen: interview compilation of the ENYGO-IJGC editorial fellows.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure.

British journal of cancer·2026
Same author

Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era.

NPJ genomic medicine·2026
Same journal

Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

Lancet (London, England)·2026
Same journal

Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

Lancet (London, England)·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Apr 4, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.8K

Endometrial cancer.

Philippe Morice1, Alexandra Leary2, Carien Creutzberg3

  • 1Department of Gynecologic Surgery, Gustave Roussy, Villejuif, France; Unit INSERM U 1030, Gustave Roussy, Villejuif, France; Université Paris-Sud (Paris XI), Le Kremlin Bicêtre, France.

Lancet (London, England)
|September 11, 2015
PubMed
Summary
This summary is machine-generated.

Endometrial cancer, primarily endometrioid adenocarcinoma, is increasingly diagnosed early. Standard treatment involves hysterectomy, with surgical and adjuvant therapies tailored to patient and disease factors for optimal survival.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.6K
Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.4K

Related Experiment Videos

Last Updated: Apr 4, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.8K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.6K
Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.4K

Area of Science:

  • Gynecologic Oncology
  • Surgical Oncology
  • Pathology

Background:

  • Endometrial cancer is the most common gynecologic malignancy in developed nations, with rising incidence.
  • The endometrioid adenocarcinoma subtype is most prevalent, often diagnosed at an early, uterus-confined stage.

Purpose of the Study:

  • To outline the current standard treatment strategies for endometrial cancer.
  • To discuss the factors influencing surgical decisions and adjuvant therapy selection.
  • To review prognostic indicators and ongoing research for high-risk patients.

Main Methods:

  • Primary treatment involves hysterectomy with bilateral salpingo-oophorectomy, frequently utilizing minimally invasive surgical techniques.
  • Lymph node management is guided by histological features, disease stage, patient characteristics, and clinical guidelines.
  • Adjuvant therapy is individualized based on tumor histology and stage to manage recurrence risk.

Main Results:

  • Five-year overall survival rates are favorable, ranging from 74% to 91% for patients without metastatic disease.
  • Risk stratification systems aid in determining postoperative management and predicting recurrence.
  • Ongoing clinical trials are evaluating novel adjuvant treatments like chemotherapy, chemoradiation, and targeted therapies for high-risk populations.

Conclusions:

  • Current management of endometrial cancer balances surgical intervention with tailored adjuvant strategies.
  • Individualized treatment approaches aim to optimize survival outcomes while minimizing adverse effects on quality of life.
  • Further research is crucial for refining treatment protocols for high-risk endometrial cancer patients.